First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Zhou, Yixin, Lin, Zuan, Zhang, Xuanye, Chen, Chen, Zhao, Hongyun, Hong, Shaodong, Zhang, LiVolume:
7
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/s40425-019-0600-6
Date:
December, 2019
File:
PDF, 928 KB
english, 2019